glp-1 super responder Hyper & hypo responders to medicines | Episode 6 The GLP-1 Super Responder Playbook

Lancet 2005;366:1279-89.PubMed 591

Semaglutide dose-dependently reduced liver enzymes, and resulted in greater NASH resolution (reduced ballooning and lobular inflammation) without worsening of fibrosis, as compared with placebo after 72 weeks of treatment

GLP-1 medications offer several advantages over insulin for many patients with Type 2 diabetes

Oral supplements go through the digestive system, which slows absorption and limits how much your body can take in at one time

This group is often interested in supporting insulin sensitivity, energy balance, and appetite signaling - not through quick-fix solutions but through structured, evidence-based exploration